Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors

被引：8

作者：

Pasi, K. John ^{[1
]}

Georgiev, Pencho ^{[2
]}

Mant, Tim ^{[3
]}

Lissitchkov, Toshko ^{[4
]}

Creagh, Michael Desmond ^{[5
]}

Bevan, David ^{[6
]}

Austin, Steve ^{[7
]}

Hay, Charles R. ^{[8
]}

Hegemann, Inga ^{[9
]}

Kazmi, Rashid ^{[10
]}

Chowdary, Pratima ^{[11
,12
]}

Ragni, Margaret V. ^{[13
,14
]}

Soh, Chang-Heok ^{[15
]}

Akinc, Akin ^{[15
]}

Partisano, Angela M. ^{[15
]}

Sorenson, Benny ^{[15
]}

Rangarajan, Savita ^{[16
]}

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Royal London Haemophilia Ctr, London, England

[2] Univ Multiprofile Hosp Act Treatment Sveti Georgi, Plovdiv, Bulgaria

[3] Quintiles Drug Res Unit, London, England

[4] SHAT Joan Pavel, Dept Coagulat Disorders & Anemia, Sofia, Bulgaria

[5] Royal Cornwall Hosp NHS Trust, Truro, England

[6] Guys & St Thomas Hosp NHS Trust, London, England

[7] St Georges Univ Hosp NHS Fdn Trust, St Georges Haemophilia Ctr, London, England

[8] Manchester Royal Infirm, Manchester, Lancs, England

[9] Univ Hosp, Zurich, Switzerland

[10] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England

[11] Royal Free Hosp, KD Haemophilia Ctr, London, England

[12] Royal Free Hosp, Thrombosis Unit, London, England

[13] Univ Pittsburgh, Div Hematol Oncol, Dept Med, Med Ctr, Pittsburgh, PA USA

[14] Univ Pittsburgh, Hemophilia Ctr Western PA, Med Ctr, Pittsburgh, PA USA

[15] Alnylam Pharmaceut, Cambridge, MA USA

[16] Guys & St Thomas NHS Fdn Trust, Ctr Haemostasis Thrombosis, London, England

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1397.1397

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1397

引用

页数：6

共 50 条

[31] Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
Adams, David
Coelho, Teresa
Conceicao, Isabel
Cruz, Marcia Waddington
Schmidt, Hartmut
Buades, Juan
Campistol, Josep
Pouget, Jean
Berk, John
Polydefkis, Michael
Ziyadeh, Nour
Partisano, Angela
Chen, Jihong
Gollob, Jared
Suhr, Ole
NEUROLOGY, 2017, 88
[32] Phase 1/2, randomized, placebo controlled and open-label extension studies of Givosiran an investigational RNA interference (RNAi) therapeutic, in patients with Acute Intermittent Porphyria
Sardh, E.
Phillips, J.
Harper, P.
Balwani, M.
Stein, P.
Rees, D.
Bloomer, J.
Bissell, D.
Desnick, R. J.
Parker, C.
Bonkovsky, H.
Al-Tawil, N.
Rock, S.
Dinh, Q.
Penz, C.
Chan, A.
Querbes, W.
Simon, A.
Anderson, K.
EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 18 - 18
[33] PHASE 2 OPEN-LABEL EXTENSION (OLE) STUDY OF PATISIRAN, AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR AMYLOIDOSIS WITH POLYNEUROPATHY
Adams, D.
Coelho, T.
Conceicao, E.
Waddington-Cruz, M.
Schmidt, H.
Buades, J.
Campistol, J. M.
Pouget, J.
Berk, J. L.
Polydefkis, M.
Ziyadeh, N.
Partisano, A. M.
Chen, J.
Gollob, J.
Suhr, O. B.
VALUE IN HEALTH, 2017, 20 (05) : A211 - A212
[34] A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results
Hill, Anita
Taubel, Jorg
Bush, Jim
Borodovsky, Anna
Kawahata, Noriyuki
Mclean, Helen
Powell, Christine
Chaturvedi, Prasoon
Warner, Garvin
Garg, Pushkal
Sorensen, Benny
BLOOD, 2015, 126 (23)
[35] A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNAI THERAPEUTIC (ALN-CC5) TARGETING COMPLEMENT C5 FOR TREATMENT OF PNH AND COMPLEMENT-MEDIATED DISEASES: INTERIM PHASE 1 STUDY RESULTS
Hill, A.
Gava, A.
Taubel, J.
Bush, J.
Borodovsky, A.
Kawahata, N.
McLean, H.
Soh, C. H.
Partisano, A.
Sorensen, B.
Najafian, N.
Urbano-Ispizua, A.
HAEMATOLOGICA, 2016, 101 : 172 - 172
[36] A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNAI THERAPEUTIC (ALN-CC5) TARGETING COMPLEMENT C5 FOR TREATMENT OF PNH AND COMPLEMENT-MEDIATED DISEASES: INTERIM PHASE 1 STUDY RESULTS
Najafian, Nader
Hill, Anita
Taubel, Jorg
Bush, Jim
Borodovsky, Anna
Kawahata, Noriyuki
Mclean, Helen
Partisano, Angela
Chaturvedi, Prasoon
Sorensen, Benny
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 153 - 153
[37] Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy: Results from the Phase 3 APOLLO study
Adams, David
Gonzalez-Duarte, Alejandra
O'Riordan, William
Yang, Chih-Chao
Yamashita, Taro
Kristen, Arnt
Tournev, Ivaylo
Schmidt, Hartmut
Coelho, Teresa
Berk, John L.
Lin, Kon-Ping
Dyck, Peter J.
Gandhi, Pritesh
Sweetser, Marianne
Chen, Jihong
Goyal, Sunita
Gollob, Jared
Suhr, Ole
NEUROLOGY, 2018, 90
[38] Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors - Results from the Phase II Study
Pipe, Steven W.
Pasi, John
Lissitchkov, Toshko
Ragni, Margaret V.
Negrier, Claude
Yu, Qifeng
Poloskey, Stacey
Mei, Baisong
Andersson, Shauna R.
BLOOD, 2020, 136
[39] Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1 (GD1): Updated Phase 2 Results
Peterschmitt, M. Judith
Lukina, Elena
Watman, Nora
Dragosky, Marta
Lastrebner, Marcelo
Pastores, Gregory
Avila Arreguin, Elsa
Phillips, Mici
Rosenbaum, Hanna
Sysoeva, Elena
Aguzzi, Rasha
Ross, Leorah
Puga, Ana Cristina
MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S52 - S52
[40] A PHASE 1/2 TRIAL OF LUMASIRAN (ALN-GO1), AN INVESTIGATIONAL RNA INTERFERENCE (RNAI) THERAPEUTIC FOR PRIMARY HYPEROXALURIA TYPE 1
Frishberg, Yaacov
Cochat, Pierre
Vant Hoff, William
Hulton, Sally
Mcgregor, Tracy L.
Haslett, Patrick
Erbe, David V.
Deschenes, Georges
PEDIATRIC NEPHROLOGY, 2018, 33 (10) : 1814 - 1815

← 1 2 3 4 5 →